P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

• S. Usmani,
• A. Hoering,
• S. Ailawadhi,
• R. Sexton,
• B. Lipe,
• J. Valent,
• M. Rosenzweig,
• J. Zonder,
• M. Dhodapkar,
• N. Callander,
• T. Zimmerman,
• P. Voorhees,
• B. Durie,
• S. V. Rajkumar,
• P. Richardson,
• R. Orlowski

Affiliations

S. Usmani

1 Memorial Sloan Kettering Cancer Center, New York

A. Hoering

2 Cancer Research And Biostatistics, Seattle

S. Ailawadhi

3 Mayo Clinic, Jacksonville

R. Sexton

2 Cancer Research And Biostatistics, Seattle

B. Lipe

4 University of Rochester Medical Center, Rochester, NY

J. Valent

5 Cleveland Clinic, Cleveland

M. Rosenzweig

6 City of Hope, Los Angeles

J. Zonder

7 Karmanos Cancer Institute, Detroit, MI

M. Dhodapkar

8 Emory Winship Cancer Institute, Atlanta GA

N. Callander

9 University of Wisconsin, Madison

T. Zimmerman

10 Beigene, Chicao

P. Voorhees

11 Levine Cancer Institute, Charlotte

B. Durie

12 Cedar Sinai Medical Center, Los Angeles

S. V. Rajkumar

13 Mayo Clinic, Rochester MN

P. Richardson

14 Dana Farber Cancer Institute, Boston MA

R. Orlowski

15 MD Anderson Cancer Center, Houston TX, United States of America